Vanguard Group Inc. Trims Stock Holdings in Elanco Animal Health Incorporated (NYSE:ELAN)

Vanguard Group Inc. decreased its position in Elanco Animal Health Incorporated (NYSE:ELAN - Free Report) by 0.4% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 48,760,977 shares of the company's stock after selling 184,506 shares during the period. Vanguard Group Inc. owned approximately 9.86% of Elanco Animal Health worth $590,495,000 at the end of the most recent quarter.

Other institutional investors have also bought and sold shares of the company. Hillsdale Investment Management Inc. boosted its stake in Elanco Animal Health by 2.1% during the fourth quarter. Hillsdale Investment Management Inc. now owns 43,300 shares of the company's stock worth $524,000 after acquiring an additional 900 shares in the last quarter. Arizona State Retirement System boosted its position in shares of Elanco Animal Health by 0.8% during the 4th quarter. Arizona State Retirement System now owns 143,462 shares of the company's stock worth $1,737,000 after purchasing an additional 1,166 shares in the last quarter. MTM Investment Management LLC grew its stake in shares of Elanco Animal Health by 9.3% in the 4th quarter. MTM Investment Management LLC now owns 14,168 shares of the company's stock valued at $172,000 after buying an additional 1,200 shares during the period. M&T Bank Corp increased its position in Elanco Animal Health by 5.9% in the 3rd quarter. M&T Bank Corp now owns 26,407 shares of the company's stock valued at $388,000 after buying an additional 1,464 shares in the last quarter. Finally, Parkman Healthcare Partners LLC raised its stake in Elanco Animal Health by 1.4% during the 3rd quarter. Parkman Healthcare Partners LLC now owns 127,812 shares of the company's stock worth $1,878,000 after buying an additional 1,770 shares during the period. Institutional investors own 97.48% of the company's stock.

Elanco Animal Health Stock Performance

Shares of NYSE ELAN traded down $0.56 during midday trading on Friday, reaching $9.17. The company's stock had a trading volume of 9,132,532 shares, compared to its average volume of 4,829,741. The stock has a market capitalization of $4.55 billion, a P/E ratio of 22.91, a PEG ratio of 2.50 and a beta of 1.44. The company has a debt-to-equity ratio of 0.66, a current ratio of 2.55 and a quick ratio of 1.31. The firm has a 50 day moving average price of $11.04 and a 200-day moving average price of $12.28. Elanco Animal Health Incorporated has a 12-month low of $8.80 and a 12-month high of $18.80.

Elanco Animal Health (NYSE:ELAN - Get Free Report) last announced its quarterly earnings data on Tuesday, February 25th. The company reported $0.14 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.15 by ($0.01). The business had revenue of $1.02 billion during the quarter, compared to the consensus estimate of $1.01 billion. Elanco Animal Health had a net margin of 4.60% and a return on equity of 6.78%. The firm's revenue for the quarter was down 1.4% compared to the same quarter last year. During the same quarter last year, the company earned $0.08 EPS. As a group, equities analysts predict that Elanco Animal Health Incorporated will post 0.91 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several research firms have recently commented on ELAN. Barclays decreased their price objective on Elanco Animal Health from $20.00 to $19.00 and set an "overweight" rating for the company in a report on Wednesday, February 26th. UBS Group reduced their price objective on shares of Elanco Animal Health from $18.00 to $17.00 and set a "buy" rating for the company in a report on Wednesday, February 26th. Morgan Stanley lowered their target price on shares of Elanco Animal Health from $14.00 to $13.00 and set an "equal weight" rating on the stock in a report on Wednesday, February 26th. Stifel Nicolaus cut their price target on Elanco Animal Health from $18.00 to $16.00 and set a "buy" rating for the company in a research note on Friday, February 21st. Finally, Piper Sandler decreased their price objective on Elanco Animal Health from $16.00 to $12.00 and set a "neutral" rating for the company in a report on Thursday, March 6th. Four research analysts have rated the stock with a hold rating and three have issued a buy rating to the company. According to MarketBeat.com, the stock currently has an average rating of "Hold" and a consensus target price of $15.17.

Insider Activity at Elanco Animal Health

In other news, Director Lawrence Erik Kurzius acquired 10,000 shares of the firm's stock in a transaction that occurred on Tuesday, March 11th. The stock was bought at an average price of $10.20 per share, with a total value of $102,000.00. Following the acquisition, the director now owns 111,459 shares in the company, valued at $1,136,881.80. The trade was a 9.86 % increase in their position. The acquisition was disclosed in a document filed with the SEC, which is accessible through the SEC website. 0.57% of the stock is owned by company insiders.

Elanco Animal Health Company Profile

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.